PLAY PODCASTS
Key Decisions in HIV Care: PrEP Considerations in Cisgender Women
Episode 151

Key Decisions in HIV Care: PrEP Considerations in Cisgender Women

In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.

Decera Clinical Education Infectious Disease Podcast · Latesha Elopre MD MSPH, Karine Lacombe MD PhD

March 24, 202238m 55s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including: 

  • Discussion of the PrEP gap and racial and gender disparities in PrEP access
  • CDC, EACS, and WHO guidance on PrEP eligibility
  • PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir
  • Data from phase III trials on the efficacy of FTC/TDF daily for women including Partners PrEP, TDF, VOICE, and FEM-PrEP
  • Pharmacokinetic data of FTC/TDF and FTC/TAF in the female genital tract and discussion of why on-demand dosing of FTC/TDF is not recommended in cisgender women
  • Data and recommendations for the use of the dapivirine ring from ASPIRE and The Ring Study and their open-label extensions, DREAM and HOPE
  • Data from the HPTN084 study on the use of long-acting cabotegravir as PrEP for cisgender women
  • Recommendations for the use of PrEP during pregnancy and breastfeeding
  • Clinical monitoring and considerations during PrEP use

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama 

Karine Lacombe, MD, PhD
Professor
UMR-S1136
Sorbonne University
Head, Infectious Diseases Department
St Antoine Hospital, AP-HP
Paris, France 

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at: 
https://bit.ly/36s2ovB

Link to full program:
https://bit.ly/3q2DlGd


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

the ring studyla cabotegravirpbmcscabotegravircab lavaginal ringcabhiv screeningbreastfeedingaspirecustomizeprep gaplong-acting cabotegravirla2-1-1partners prepon-demandcdc guidelineshptn 084dpvpre-exposure prophylaxiscisgender womenla cabcabotegravir lacabotegravir imhiv-1 rna2:1:1antiretroviral therapyprepcervicovaginal tissueprep adherencepregnancystopping prepcdc guidancefem-prepemtricitabine/tenofovir alafenamideeacshiv testingtdf2delayed diagnosisstarting prepemtricitabine/tenofovirprep eligibilitydreampharmacokineticsvoicelong-actingftc/tdfdapivirinehopewhohiv incidenceftc/tafartintramuscularhivfemale genital tract